Opus Point Partners Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Opus Point Partners Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$261K	Sell	3,926 -1,946	-33%	-$131K	0.47%	47
2019 Q2	$467K	Buy	5,872 +116	+2%	+$10.4K	0.69%	37
2019 Q1	$644K	Buy	5,756 +2,222	+63%	+$243K	0.87%	25
2018 Q4	$356K	Sell	3,534 -464	-12%	-$48.1K	0.78%	21
2018 Q3	$505K	Hold	3,998	–	–	1.21%	25
2018 Q2	$335K	Sell	3,998 -498	-11%	-$36.5K	0.73%	33
2018 Q1	$277K	Buy	4,496 +717	+19%	+$43.2K	0.54%	42
2017 Q4	$221K	Sell	3,779 -702	-16%	-$44.3K	0.19%	57
2017 Q3	$260K	Buy	4,481 +2,661	+146%	+$287K	0.23%	56
2017 Q2	$220K	Sell	1,820 -1,492	-45%	-$173K	0.2%	62
2017 Q1	$375K	Buy	3,312 +1,177	+55%	+$137K	0.28%	59
2016 Q4	$232K	Buy	2,135 +829	+63%	+$98.8K	0.18%	55
2016 Q3	$215K	Buy	+1,306	New	+$206K	0.12%	42

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Opus Point Partners Management's ICPT Position: Q3 2019 in Review

Opus Point Partners Management reduced its Intercept Pharmaceuticals, Inc. (ICPT) stake by 33% in Q3 2019, selling an estimated $131K and leaving 3,926 shares worth $261K. The position accounts for 0.47% of the portfolio, ranked #47.

Opus Point Partners Management first reported a position in ICPT in Q3 2016 and has held it in 13 quarters since. The position peaked at $644K in Q1 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q3 2019.

Opus Point Partners Management held 3,926 shares of Intercept Pharmaceuticals, Inc. worth $261K as of Q3 2019.
Opus Point Partners Management sold 1,946 Intercept Pharmaceuticals, Inc. shares in Q3 2019, an estimated $131K.
Intercept Pharmaceuticals, Inc. made up 0.47% of Opus Point Partners Management's portfolio in Q3 2019, its #47 holding.
Opus Point Partners Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2016 and has held it in 13 quarters since.
Opus Point Partners Management's Intercept Pharmaceuticals, Inc. position peaked at $644K in Q1 2019.
188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.